Clinical trials: sponsored by AstraZeneca
Dyslipidemia
Hs-CRP as Clinical Marker of Inflammatory Atherogenic Dyslipidemia
The objective of this proposal is to study the applicability of the hs-CRP assay in the assessment of CV risk in daily clinical conditions where hyperlipidemic population with or without CHD are currently evaluated.
- Trial name
- NCT00169871
- Where
- Canada
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- CHU de Quebec-Universite Laval
Hypertension
Dose Ranging, Safety and Tolerability of TOPROL-XL® Extended-Release Tablets in Hypertensive Pediatric Subjects
This was a 4-week, multicenter, double-blind, placebo-controlled, randomized, parallel-group study to determine the antihypertensive dose range, efficacy, safety and tolerability of TOPROL-XL ® (metoprolol succinate)…
- Trial name
- 307A (NCT00255528)
- Testing
- metoprolol succinate
- Where
- 31 sites in United States, Dominican Republic
- Volunteers
- 144 people
- Sponsor
- AstraZeneca
Breast Cancer
Neoadjuvant Hormonal Treatment of Postmenopausal Women Who Have Operable Breast Cancer
EFFICACY OF NEOADJUVANT ENDOCRINE THERAPY WITH ANASTROZOLE IN POMENOPAUSAL WOMEN WITH ER-POSITIVE BREAST CANCER. Flavia Morales-Vásquez, Horacio Noé López Basave.
- Trial name
- NCT00437853
- Testing
- Anastrozole
- Where
- Mexico
- Volunteers
- 30 people
- Sponsor
- Instituto Nacional de Cancerologia de Mexico
Breast Neoplasms
SAKK - a Trial to Evaluate Antitumor Efficacy of Faslodex® After Aromatase Inhibitor Failure in Advanced Breast Cancer
The primary objective of the study is to assess the activity of fulvestrant in postmenopausal women with advanced breast cancer failing treatment with non-steroidal or steroidal aromatase inhibitors by estimating the Clinical…
- Trial name
- NCT00272740
- Testing
- Fulvestrant
- Where
- 8 sites in Belgium, Switzerland
- Volunteers
- 93 people
- Sponsor
- AstraZeneca
Hypertrophic Cardiomyopathy
CHANCE - Candesartan in Hypertrophic Cardiomyopathy
The primary hypothesis of the study is that treatment with AT1-R antagonist in patients with nonobstructive form of HCM will be first save, second will cause regression of myocardial hypertrophy.
- Trial name
- NCT00430833
- Testing
- candesartan
- Where
- Czechia
- Sponsor
- Charles University, Czech Republic
Atrial Fibrillation
Candesartan in the Prevention of Relapsing Atrial Fibrillation
The purpose of this study is to test the hypothesis that treatment with the angiotensin II type 1 receptor antagonist candesartan may reduce the recurrence rate of atrial fibrillation after electrical cardioversion.
- Trial name
- NCT00130975
- Testing
- Candesartan
- Where
- 2 sites in Norway
- Volunteers
- 200 people
- Sponsor
- Asker & Baerum Hospital
Social Anxiety Disorder
Quetiapine in Social Anxiety Disorder
The purpose of the study is to examine the effectiveness and tolerability of quetiapine for the treatment of social anxiety disorder (SAD).
- Trial name
- NCT00215254
- Testing
- quetiapine
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Duke University
Cystic Fibrosis
Non-Invasive Biomarkers in Cystic Fibrosis
Background Chronic airway inflammation is present in cystic fibrosis. Non-invasive inflammometry may be useful in disease management.
- Trial name
- NCT00413140
- Where
- 4 sites in Netherlands
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Maastricht University Medical Center
Asthma, Cystic Fibrosis
FLAME: Airway Inflammation Monitoring in Asthma and Cystic Fibrosis
Background By means of measurements of series of non-invasive inflammatory markers in exhaled breath (condensate), a reflection of inflammatory processes and oxidative stress, can be obtained.
- Trial name
- NCT00404859
- Where
- 4 sites in Netherlands
- Volunteers
- 70 people
- Sponsor
- Maastricht University Medical Center
Asthma, Healthy
Inflammatory Markers in Exhaled Breath (Condensate) in Childhood Asthma
Background: Exhaled nitric oxide and inflammatory biomarkers in exhaled breath condensate may be useful to diagnose and monitor childhood asthma.
- Conditions
- Asthma, Healthy, Children
- Trial name
- NCT00404976
- Where
- Netherlands
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Maastricht University Medical Center
Asthma
The Anti-Inflammatory Effect of Extrafine HFA-Beclometasone Versus HFA-Fluticasone, by Means of Inflammometry
Background Chronic inflammation in peripheral airways plays an important role in the pathophysiology of asthma. Extrafine hydrofluoroalkane (HFA) beclometasone is distinguished from other ICS because of its fine aerosol…
- Trial name
- NCT00402207
- Testing
- extrafine HFA-beclomethasone, HFA-fluticasone
- Where
- Netherlands
- Volunteers
- 33 people
- Sponsor
- Maastricht University Medical Center
Hypercholesterolemia, Coronary Heart Disease
Evaluation of the Efficacy of Rosuvastatin in Daily Practice (TARGET)
In this study the effect of the switch to rosuvastatin from another statin (fluvastatin, pravastatin, simvastatin, atorvastatin) was evaluated in high-risk patients with and without evident CHD and LDL-C ≥ 3.2 mmol/l.
- Trial name
- NCT00396110
- Volunteers
- 3,889 people
- Sponsor
- AstraZeneca
Schizophrenia
Cognition, Functioning and Quality of Life
People affected by schizophrenia often experience poor concentration, lapses in memory and difficulty with completing tasks; and this set of problems are known as neuro-cognitive deficits.
- Trial name
- NCT00182442
- Testing
- Olanzapine & Quetiapine
- Where
- Canada
- Volunteers
- 80 people
- Sponsor
- Hamilton Health Sciences Corporation
Psychotic Disorders, Schizophrenia
A Comparative Study of New Medications for Psychosis in Adolescents
The overall goal of this study is to determine the efficacy and tolerability of three atypical antipsychotic medications (risperidone, olanzapine, and quetiapine) in the treatment of adolescents with psychosis.
- Conditions
- Psychotic Disorders, Schizophrenia, Schizophreniform Disorders, Schizoaffective Disorders
- Trial name
- NCT00222495
- Testing
- quetiapine, olanzapine, risperidone
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of Minnesota
Type 2 Diabetes
GLAD: Dose-Finding, Efficacy, and Safety of AZ 242 (Tesaglitazar) in Subjects With Type 2 Diabetes
This is a 12-week randomized, double-blind, multi-center, active-controlled (open-label pioglitazone) and placebo-controlled study of tesaglitazar (0.1, 0.5, 1, 2, and 3 mg) in patients with type 2 diabetes, not adequately…
- Trial name
- NCT00280865
- Testing
- Tesaglitazar, Pioglitazone, Dietary and Lifestyle Modification Counseling
- Where
- 110 sites in United States, Canada and 2 more
- Volunteers
- 500 people
- Sponsor
- AstraZeneca
Diabetes, Type I
Diabetes Type 1, Treatment Study Atacand/Placebo After Kidney Biopsy
The type 1 diabetes patients who were still normoalbuminuric and normotensive, after 17 years duration and a second research kidney biopsy, could enter the double blind treatment study of Atacand or Placebo.
- Trial name
- NCT00328302
- Testing
- Candesartan
- Where
- Sweden
- Volunteers
- 13 people
- Sponsor
- Karolinska University Hospital
Acute Myocardial Infarction
Efficacy and Safety of Adding Clopidogrel to Aspirin or Use of Metoprolol in Myocardial Infarction
COMMIT/CCS2 is a large randomised trial of the effects of clopidogrel plus Aspirin versus Aspirin alone in acute heart disease. Patients presenting within 24 hours of the onset of suspected acute MI were potentially eligible…
- Trial name
- NCT00222573
- Testing
- clopidogrel and metoprolol
- Where
- 2 sites in China, United Kingdom
- Volunteers
- 46,000 people
- Sponsor
- University of Oxford
Schizophrenia, Substance Use Disorders
The Impact of Quetiapine on the Drug Abuse Patterns of Addicted Schizophrenic Patients
The lifetime of substance use disorders in schizophrenia is close to 50%. Substance abuse in schizophrenia is associated with negative consequences.
- Trial name
- NCT00295412
- Testing
- quetiapine (drug)
- Where
- Canada
- Sponsor
- Université de Montréal
Breast Cancer
STARS Breast Trial (Study of Anastrozole and Radiotherapy Sequencing Pilot)
This is a randomized study comparing the use of Anastrozole before and continuing during radiotherapy for breast cancer compared to the use of anastrozole after irradiation.
- Trial name
- NCT00126360
- Testing
- Timing of Anastrozole in respect to radiotherapy
- Where
- 4 sites in Australia
- Volunteers
- 100 people
- Sponsor
- St George Hospital, Australia